Control of Tumors by Antigen-Specific CD8+T Cells through PDL1-Targeted Delivery of Antigenic Peptide

Po Hao Feng, Xiaoxu Wang, Louise Ferrall, T. C. Wu, Chien Fu Hung

研究成果: 雜誌貢獻文章同行評審


Tumor antigen-specific T cell function is limited by immune tolerance in the tumor microenvironment. In the tumor microenvironment, tumor cells upregulate PD-L1 expression to promote T cell exhaustion by PD-1/PD-L1 interactions and undergo mutations to avoid being targeted by tumor antigen-specific T cells. Thus, tumor cells escape the immune surveillance by causing immune tolerance. We reason that a chimeric molecule made of a PD-L1-specific antibody linked to a cleavable antigenic peptide can target the antigenic peptide to the tumor microenvironment, resulting in the blockade of the PD-1/PD-L1 pathway and killing tumor cells through the coating of antigenic peptide. Here, we have generated a therapeutic chimeric protein containing the PD-L1 single-chain variable fragment (scFv) linked to a cleavable model cytotoxic T lymphocyte (CTL) epitope: E7 CTL peptide. Our study demonstrated that our chimeric protein (named PDL1-scFv-Fc-RE7) can target PD-L1-expressing tumor cells and enable E7 presentation by releasing cleavable E7 CTL peptide to coat tumor cells, resulting in tumor clearance by E7-specific CD8+ T cells. The presentation of the E7 peptide by cancer cells can then render tumor cells susceptible to the killing of preexisting E7-specific CD8+ T cells and contribute to tumor clearance. Our finding suggests a synergistic approach to not only enhance antigen-specific tumor clearance but also bypass immune tolerance.
期刊Journal of Immunology Research
出版狀態已發佈 - 2022

ASJC Scopus subject areas

  • 免疫學和過敏
  • 免疫學


深入研究「Control of Tumors by Antigen-Specific CD8+T Cells through PDL1-Targeted Delivery of Antigenic Peptide」主題。共同形成了獨特的指紋。